Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group B vaccine (recombinant, adsorbed) (Pfizer)
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Trumenba (meningococcal group B vaccine [recombinant, adsorbed]) is a sterile suspension for intramuscular injection developed by Pfizer. It is a recombinant, bivalent protein subunit vaccine consisting of two lipidated recombinant factor H binding protein (fHBP) variants from *Neisseria meningitidis* serogroup B. One variant is from fHBP subfamily A and the other from subfamily B. fHBP is a surface-exposed lipoprotein that binds human factor H, allowing the bacteria to evade the host's complement-mediated killing. By targeting fHBP, the vaccine induces bactericidal antibodies that provide protection against invasive meningococcal disease caused by serogroup B strains. It was granted FDA Breakthrough Therapy designation in March 2014 and is approved for use in individuals aged 10 through 25 years.
- Brand names
- Trumenba
- Other names
- bivalent rLP2086 meningococcal serogroup B vaccinemeningococcal serogroup B vaccinefHBP vaccine
02
Targets
CFH (Complement factor H)fHbp (Factor H-binding protein)Neisseria meningitidis factor H binding protein subfamily B
Beyond the preview
Go deeper on meningococcal group B vaccine (recombinant, adsorbed) (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group B vaccine (recombinant, adsorbed) (Pfizer).